Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel

CompletedOBSERVATIONAL
Enrollment

115

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

May 15, 2020

Study Completion Date

May 15, 2020

Conditions
Neuroendocrine Tumors
Interventions
OTHER

Data collection

The study is an observational evaluation that does not affect physician practices, the physician-patient relationship, or the care of subjects. The prescriptions will be decided prior to inclusion of the subject into the study. The information will be recorded using the data available in the medical file or collected during the visit (as part of the routine subject management).

Trial Locations (1)

Unknown

Ipsen Central Contact, Paris

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT03562091 - Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel | Biotech Hunter | Biotech Hunter